


### Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula I:



FORMULA I

or a pharmaceutically acceptable salt, ~~enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof~~, wherein:

R<sup>1</sup> is selected from the group consisting of C<sub>6-10</sub> aryl, ~~C<sub>5-10</sub> heteroaryl or C<sub>5-10</sub> heterocyclic~~ groups, said aryl, ~~heteroaryl and heterocyclic~~ groups optionally substituted with 1 to 3 groups of R<sup>a</sup>;

R<sup>a</sup> is selected from the group consisting of C<sub>1-6</sub>alkyl, ~~and halogen, hydroxy,~~ aryl(C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkoxy(C<sub>1-6</sub>)alkyl, ~~halo(C<sub>1-6</sub>)alkyl, nitro, amino,~~ mono- or di-N-(C<sub>1-6</sub>)alkylamino, ~~acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C<sub>1-6</sub>)alkylcarbamoyl, (C<sub>1-6</sub>)alkoxycarbonyl,~~ aryloxy carbonyl, ~~ureido, guanidine, sulphonylamino, aminosulphonyl, (C<sub>1-6</sub>)alkylthio,~~ (C<sub>1-6</sub>)alkylsulphinyl, (C<sub>1-6</sub>)alkylsulphonyl, ~~heterocyclyl, and heterocyclyl(C<sub>1-6</sub>)alkyl~~ groups; and

R is selected from the group consisting of C<sub>1-8</sub>alkyl, ~~C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> heterocycloalkyl, C<sub>5-10</sub> heteroaryl, and C<sub>5-11</sub> heterocyclic~~ groups, said ~~heteroaryl and heterocyclic~~ groups are optionally substituted with 1 to 3 groups of R<sup>a</sup> and said C<sub>1-8</sub>alkyl groups are substituted with 1 to 3 groups selected from the group consisting of aryl, ~~heterocyclyl, (C<sub>1-6</sub>)alkylthio, cyano, heteroaryl, guanidino,~~ ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino, ((2-amino)prop-2-yl)

~~carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl-sulfonyl,  
(C<sub>2-6</sub>)alkenylthio, (C<sub>2-6</sub>)alkynylthio, amino, mono- or di-(C<sub>1-6</sub>)alkylamino, arylthio,  
heterocyclylthio, (C<sub>1-6</sub>)alkoxy, aryl(C<sub>1-6</sub>)alkoxy, aryl(C<sub>1-6</sub>)alkylthio, cycloalkyl,  
cycloalkenyl, carboxy and esters thereof, hydroxy and halogen groups.~~

2-3. (Canceled)

4. (Currently Amended) The compound according to claim 1, wherein R<sup>1</sup> is a phenyl group optionally substituted with 1 to 3 groups of R<sup>a</sup> and ~~R is a heterocycloalkyl or heteroaryl group.~~

5. (Currently Amended) The compound according to claim 1, R<sup>1</sup> is a phenyl group substituted with 1 to 3 groups of ~~methoxy, halogen, methyl, ethyl, propyl, butyl, naphthyl, 5-(2-pyridyl)thiophen-2-yl or a mixture thereof, and R is a heterocycloalkyl or heteroaryl group.~~

6. (Currently Amended) The compound according to claim 1, wherein the compound is selected from the group consisting of:


N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;























~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide;~~





















compounds provided in ~~tables 1 and 2~~ Table 1 below





















Table 1













































Example #	R <sub>1</sub>	R <sub>2</sub>
3		
4		
5		
6		
7		
8		
9		
10		
11		

13		
14		
15		
16		
17		
19		
20		
21		
22		
23		
26		





















28		
29		
30		
31		
32		
33		
34		
35		
36		
37		



















38		
39		
40		
41		
42		
43		
44		
45		
46		
48		

49		
50		
51		
52		
53		
56		
57		
58		
59		
60		
61		

62		
63		
64		
65		
66		
67		
69		
70		
71		
72		



73		
74		
76		
77		
78		
79		
84		
85		
86		
87		

88		
89		
94		
95		
96		
97		
99		
100		
101		

102		
104		
105		
106		
107		
108		
109		
110		
111		
113		

117		
119		
120		
122		
125		
126		
127		
130		
132		
133		
134		


























135		
136		
138		
140		
141		
142		
143		
144		

Table 2



Example #	R <sub>1</sub>	R <sub>2</sub>
-----------	----------------	----------------

146		Me
147		Me
148		Me
149		H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, ~~enantiomers, diastereomers, in vivo hydrolysable esters and mixtures thereof.~~

7. (Currently Amended) The compound according to claim 6, wherein the compound is selected from the group consisting of:

N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers, diastereomers, in vivo hydrolysable esters and mixtures thereof.~~


8. (Currently Amended) The compound according to claim 7, wherein the compound is selected from the group consisting of: N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-

acetamide; and pharmaceutically acceptable salts, ~~enantiomers, diastereomers, in-vivo hydrolysable esters~~ and mixtures thereof.

9. (Previously Presented) A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

10. (Withdrawn - Currently Amended) A method of inhibiting activity of lethal factor (LF) released from bacterial in a mammal, the method comprising:

administering to a patient in need thereof a therapeutically effective amount of a compound of structural formula I



FORMULA I

or a pharmaceutically acceptable salt, ~~enantiomer, diastereomer or in-vivo hydrolysable ester~~ or mixture thereof, wherein,

R<sup>1</sup> is selected from the group consisting of C<sub>6-10</sub> aryl, ~~C<sub>5-10</sub> heteroaryl and C<sub>5-10</sub> heterocyclic~~ groups, said aryl, ~~heteroaryl and heterocyclic~~ groups optionally substituted with 1 to 3 groups of R<sup>a</sup>;

R<sup>a</sup> is selected from the group consisting of C<sub>1-6</sub>alkyl, ~~and halogen, OH, aryl(C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkoxy(C<sub>1-6</sub>)alkyl, halo(C<sub>1-6</sub>)alkyl, nitro, amino, mono- or di-N-(C<sub>1-6</sub>)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C<sub>1-6</sub>)alkylcarbamoyl, (C<sub>1-6</sub>)alkoxycarbonyl, aryloxy carbonyl, ureido, guanidine, sulphonylamino, aminosulphonyl, (C<sub>1-6</sub>)alkylthio, (C<sub>1-6</sub>)alkylsulphinyl, (C<sub>1-6</sub>)alkylsulphonyl, heterocyclyl, and heterocyclyl(C<sub>1-6</sub>)alkyl~~ groups; and

R is selected from the group consisting of ~~C<sub>1-8</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> heterocycloalkyl, C<sub>5-10</sub> heteroaryl, or C<sub>5-11</sub> heterocyclyl~~, said heteroaryl and heterocyclyl

groups are optionally substituted with 1 to 3 groups of  $R^a$ ; and said  $C_{1-8}$  alkyl groups are substituted with 1 to 3 groups selected from the group consisting of aryl, heterocycetyl,  $(C_{1-6})$ alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino, ((2-amino)prop-2-yl)carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl,  $(C_{2-6})$ alkenylthio,  $(C_{2-6})$ alkynylthio, amino, mono- or di- $(C_{1-6})$ alkylamino, arylthio, heterocycetylthio,  $(C_{1-6})$ alkoxy, aryl $(C_{1-6})$ alkoxy, aryl $(C_{1-6})$ alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen groups.

11. (Withdrawn - Currently Amended) The method according to claim 10, wherein the compound is selected from the group consisting of:


N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide;





















compounds provided in ~~tables 1 and 2~~ Table 1 below





















Table 1











































Example #	$R_1$	$R_2$
3		
4		













































5		
6		
7		
8		
9		
10		
11		
13		
14		
15		





















16		
17		
19		
20		
21		
22		
23		
26		
28		
29		





















30		
31		
32		
33		
34		
35		
36		
37		
38		
39		

40		
41		
42		
43		
44		
45		
46		
48		
49		
50		





















51		
52		
53		
56		
57		
58		
59		
60		
61		
62		
63		

























64		
65		
66		
67		
69		
70		
71		
72		
73		
74		

76		
77		
78		
79		
84		
85		
86		
87		
88		
89		

90		
94		
95		
96		
97		
99		
100		
101		
102		
104		



105		
106		
107		
108		
109		
110		
111		
113		
117		
119		

120		
122		
123		
125		
126		
127		
130		
132		
133		
134		
135		
136		






















138		
140		
141		
142		
143		
144		

Table 2



Example #	R <sub>1</sub>	R <sub>2</sub>
146		Me
147		Me
148		Me

149		H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, ~~enantiomers, diastereomers, in vivo hydrolysable esters~~ and mixtures thereof.

12. (Withdrawn - Currently Amended) The method according to claim 11, wherein the compound is selected from the group consisting of:

N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;

~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide;~~ and pharmaceutically acceptable salts, ~~enantiomers, diastereomers, in vivo hydrolysable esters~~ and mixtures thereof.

13. (Withdrawn - Currently Amended) The method according to claim 12, wherein the compound is selected from the group consisting of:

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide; and pharmaceutically acceptable salts, ~~enantiomers, diastereomers, in vivo hydrolysable esters~~ and mixtures thereof.

14. (Withdrawn) The method according to claim 10, wherein said administering further comprises administering the compound of formula I in combination with one or more known drugs selected from beta-lactams, aminoglycosides, inhibitors of

beta-lactamase, renal tubular blocking agents and inhibitors or metabolizing enzymes, N-acylated amino acids.

15. (Withdrawn) The method according to claim 14, wherein the known drugs are selected from the group consisting of imipenem, meropenem, vancomycin, cilastatin, cefoxitin, penicillin, clavulanic acid, probenecid, tetracycline, ciprofloxacin, and norfloxacin or a mixture thereof, wherein when imipenem is used as a drug it is used in combination with cilastatin as PRIMAXIN®.